Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis
Authors:
- Katarzyna KlasKKKatarzyna Klas
- Karolina StrzebonskaKSKarolina Strzebonska
- Lucja ZaborowskaLZLucja Zaborowska
- Tomasz KrawczykTKTomasz Krawczyk
- Alicja WłodarczykAWAlicja Włodarczyk
- Urszula Bąk-KuchejdaUBUrszula Bąk-Kuchejda
- Maciej PolakMPMaciej Polak
- Simon Van WambekeSWSimon Van Wambeke
- Marcin WaligoraMWMarcin Waligora
Open Access
- 26 October 2024
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (1) , 89-101
Abstract
Background Oncology research is increasingly adopting new clinical trial models that implement the concept of precision medicine. One of these is the basket clinical trial design. Basket clinical trials allow new treatments to be evaluated across multiple tumor types. Patients recruited to basket clinical trials share certain molecular characteristics of their cancer that are predictive of clinical benefit from the experimental treatment. Objective Our aim was to describe the risks and benefits of basket clinical trials in oncology. Methods Our study was prospectively registered in PROSPERO (CRD42023406401). We systematically searched PubMed, Embase, and ClinicalTrials.gov for reports of basket clinical trials in oncology published between 1 January, 2001, and 14 June, 2023. We measured the risk by treatment-related adverse events (grades 3, 4, and 5), and the benefit by objective response rate. We also extracted and analyzed data on progression-free survival and overall survival. When possible, data were meta-analyzed. Results We included 126 arms of 75 basket clinical trials accounting for 7659 patients. The pooled objective response rate was 18.0% (95% confidence interval [CI] 14.8–21.1). The rate of treatment-related death was 0.7% (95% CI 0.4–1.0), while 30.4% (95% CI 24.2–36.7) of patients experienced grade 3/4 drug-related toxicity. The median progression-free survival was 3.1 months (95% CI 2.6–3.9), and the median overall survival was 8.9 months (95% CI 6.7–10.2). Conclusions Our results provide an empirical basis for communicating about the risks and benefits of basket clinical trials and for refining new models of clinical trials applied in precision medicine.Keywords
Funding Information
- Narodowe Centrum Nauki (UMO-2019/35/N/HS1/00178, UMO-2021/41/B/HS1/01123)
This publication has 43 references indexed in Scilit:
- Revolutionizing cancer drug development: Harnessing the potential of basket trialsCancer, 2023
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysisCancer, 2022
- Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-AnalysisTargeted Oncology, 2021
- Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTargeted Oncology, 2020
- The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature ReviewClinical Therapeutics, 2020
- New clinical trial designs in the era of precision medicineMolecular Oncology, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid CancersJAMA Oncology, 2018
- Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutationsInvestigational New Drugs, 2017
- Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticiansStatistics in Medicine, 2000